Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11

11 décembre 2017

12:36
Aesculap Biologics, LLC is pleased to announce the launch of its redesigned website. The new website has a clean, uncluttered design, improved functionality, and enhanced rich content to provide both healthcare professionals and patients with...

11:03
Results from a post hoc subgroup analysis of the Phase II SUSTAIN study show that crizanlizumab, an investigational humanized anti-P-selectin monoclonal antibody, delayed the time to first sickle cell pain crisis (SCPC) in patients vs. placebo in key...

10:00
BioMarin Pharmaceutical Inc. announced updates on valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia at ASH. Efficacy Data with Valoctocogene Roxaparvovec...

10:00
AbbVie , a global biopharmaceutical company, today announced new data on the biologic and cellular mechanisms of IMBRUVICA® (ibrutinib) in patients with chronic graft-versus-host disease (cGVHD), a potentially life-threatening consequence of an...

10:00
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a Sponsored Research Agreement (SRA) with The Rockefeller University to expand its research efforts around the mechanisms by which the CA125 tumor shed antigen...

09:07
Dermaclara, developers of the popular stretch mark and wrinkle skincare Silicone Fusion Treatment, recently concluded two independent clinical studies confirming the effectiveness of Silicone Fusion Technology, their breakthrough anti-aging skin care...

09:00
Telephus Biosciences ("Telephus"), a biotechnology company focused on discovering and developing innovative immunotherapy products to treat life-threatening antibiotic-resistant infections, announced today the appointment of three key opinion leaders...

08:30
As previously informed, the Phase III trial, ADMYRE, which compared plitidepsin in combination with dexamethasone versus dexamethasone alone met its primary endpoint, progression free survival, and secondary objectives, overall survival and safety...

08:20
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a data presentation, at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta,...

08:10
CytoSorbents Corporation , a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the German Federal Ministry of Education...

08:00
Sophiris Bio Inc. (the "Company" or "Sophiris") today announced that it has completed enrollment in its Phase 2b study to evaluate the safety and tolerability of topsalysin in treating men with clinically significant localized prostate cancer....

08:00
Genomic Health, Inc.  today announced results of 10 studies that reinforce the unmatched value of the Oncotype DX Breast Recurrence Score® test and Oncotype DX® DCIS Scoretm test in optimizing patient treatment across the breast cancer disease...

07:05
RXi Pharmaceuticals Corporation announced today that it has entered into a research collaboration with Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) to explore potential synergies of using RXi's self-delivering RNAi technology (sd-rxRNA®) in...

06:45
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults. Galcanezumab has been submitted for use as a...

06:01
Eating yogurt on a regular basis may help reduce measures of chronic inflammation in women and support a healthy digestive system, researchers from University of Wisconsin-Madison College of Agricultural and Life Sciences (UW-Madison) report in the...

05:41
NeuroVive Pharmaceutical AB and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' joint project KL1333, an investigational treatment for genetic mitochondrial disorders, including MELAS (Mitochondrial...

03:00
Results published in Diabetes, Obesity and Metabolism    Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes...

02:00
Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that the results of the Global Phase 3 study (MAVORIC: Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of...

02:00
Kyowa Hakko Kirin Co., Ltd. (Tokyo : 4151, Nobuo Hanai président-directeur général de « Kyowa Hakko Kirin ») a annoncé aujourd'hui que les résultats de l'étude globale en phase 3 (MAVORIC : Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL -...

02:00
Interim data provides important real world insights into the treatment pathway of patients in the UK with chronic myeloid leukaemia    In patients with a suboptimal response in first line; higher rates of subsequent ELN optimal response were...

01:23
Nordic Nanovector ASA (OSE: NANO) has presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory (R/R) indolent NHL (iNHL) at the 59th Annual ASH meeting...


10 décembre 2017

11:40
A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with axicabtagene ciloleucel, offered commercially under the brand name Yescartatm, remain in remission 15...

10:47
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriahtm (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r)...

10:30
For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight...

08:48
Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality...

08:32
The number of variants identified as being associated with cancer risk and progression is rapidly growing. Meanwhile, advances in medical genomics are paving the way to novel approaches for the diagnosis, management, and treatment of patients with...

08:00
Blueprint Medicines Corporation , a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new data from its ongoing Phase 1 clinical trial of avapritinib (formerly known as...

08:00
PharmaEssentia USA, a subsidiary of PharmaEssentia Corporation (Taipei Exchange: 6446), today announced the latest follow-up results of Ropeginterferon alfa-2b from the ongoing, long-term, follow-up trial CONTINUATION-PV (CONTI-PV) for patients with...


9 décembre 2017

14:00
Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute...

12:05
Today, Janssen Research & Development, LLC (Janssen) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with IMBRUVICA® (ibrutinib). The extended follow-up data demonstrated that patients...

12:03
AbbVie , a global biopharmaceutical company, today announced pooled analysis results of the longest follow-up data to date in Bruton's tyrosine kinase (BTK) inhibition for relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients treated with...

10:00
Early evidence suggests that gene therapy developed at St. Jude Children's Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. Preliminary results from...

10:00
In four studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers announce promising findings on innovative tools and therapies for hard-to-treat blood disorders including...

09:43
In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting...

09:00
ARMO BioSciences, Inc., a late-stage immuno-oncology company, today released additional clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin) in non-small cell lung cancer (NSCLC). In 27 NSCLC patients who...

09:00
AbbVie , a global biopharmaceutical company, today announced new three-year follow-up data from the RESONATEtm-2 study (PCYC-1115/1116), which found that previously-untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients...

07:30
BioMarin Pharmaceutical Inc. announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia A. The...


8 décembre 2017

18:00
Seno Medical Instruments, Inc. (Seno Medical), the leader in new technology for breast cancer diagnosis using opto-acoustic (OA/US) imaging to differentiate benign from malignant masses, reported clinical data from their clinical study demonstrating...

17:00
Eli Lilly and Company today announced top-line results from its Phase 3 RAINFALL study of CYRAMZA® (ramucirumab) in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) in the first-line treatment of patients with HER2-negative...

12:37
Eisai today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (Halaven®), in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside of the United States and Canada) anti-PD-1...

11:58
Food Safety and Technology Research Centre of the Department of Applied Biology and Chemical Technology (ABCT), The Hong Kong Polytechnic University (PolyU) recently found that bacteria that carry the colistin resistance gene mcr-1 commonly exist in...

11:06
Dentists rely on composite materials to perform restorative procedures, such as filling cavities. Yet these materials, like tooth enamel, can be vulnerable to the growth of plaque, the sticky biofilm that leads to tooth decay. In a new study,...

08:08
Eisai Inc. today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (marketed as HALAVEN®, "eribulin"), in combination with the Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and...

02:30
ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced additional clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin) in metastatic renal cell carcinoma (mRCC).  In patients with...

01:18
Sandoz, a division of Novartis and the global leader in biosimilars, today announced data demonstrating the pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity of proposed biosimilar pegfilgrastim as compared to the reference...


7 décembre 2017

16:22
Sangamo Therapeutics, Inc. announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion on the application for orphan medicinal product designation (OMPD) for SB-318 and...

16:10
NxStage Medical, Inc. , a leading medical technology company focused on advancing renal care, today announced new results in Hemodialysis International, demonstrating its remote patient management system, Nx2me Connected Health, reduces home...

16:02
Novartis announced today the initiation of the ASLeap trial in patients with ankylosing spondylitis (AS), evaluating the effect of changing to a higher dose (300 mg) of Cosentyx® (secukinumab) in patients who do not achieve symptom remission after...

14:36
Oncotarget, the world's largest oncology peer-reviewed research publication, awarded travel grants enabling four biomedical researchers to attend November's Frontiers in Cancer Science 2017 (FCS 2017) conference in Singapore. The travel sponsorship...

10:38
Circadian rhythms affect some of the most crucial functions in the human body, from sleep and mental health to metabolism and defending against deadly diseases such as cancer. After decades of research that helped...

1 2 3 4 5 6 7 8 9 10 11